- Home
- GIGM vs GTBP Comparison
GIGM vs GTBP Comparison
Compare GIGM & GTBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GIGM | GTBP |
|---|---|---|
| Founded | 1998 | 1965 |
| Country | Taiwan | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.9M | 17.7M |
| IPO Year | 2002 | 2016 |
Fundamental Metrics
Financial Performance| Metric | GIGM | GTBP |
|---|---|---|
| Price | $1.33 | $0.33 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 5.1K | ★ 900.9K |
| Earning Date | 05-12-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.75 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.29 | $0.26 |
| 52 Week High | $1.89 | $2.11 |
Technical Indicators
Market Signals| Indicator | GIGM | GTBP |
|---|---|---|
| Relative Strength Index (RSI) | 39.80 | 37.65 |
| Support Level | $1.30 | $0.31 |
| Resistance Level | $1.51 | $0.48 |
| Average True Range (ATR) | 0.06 | 0.04 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 8.70 | 9.79 |
Price Performance
Historical ComparisonAbout GIGM GigaMedia Limited
GigaMedia Ltd is a diversified provider of digital entertainment services. The only segment and principal business of the company is digital entertainment service business, that operates a portfolio of digital entertainment products, targeting digital entertainment service users across Asia. The company operates digital entertainment business in Taiwan, Hong Kong and Macau through FunTown. The company generates majority revenue from Taiwan.
About GTBP GT Biopharma Inc.
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. The company is engaged in discovering, developing, and commercializing therapeutics from its proprietary product platform across various disease areas, mainly focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platform offers immuno-oncology products designed to treat hematologic malignancies, sarcoma, and solid tumors.